Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.

OBJECTIVE:The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorder...

Full description

Bibliographic Details
Main Authors: Bernhard Moser, Anna Megerle, Christine Bekos, Stefan Janik, Tamás Szerafin, Peter Birner, Ana-Iris Schiefer, Michael Mildner, Irene Lang, Nika Skoro-Sajer, Roela Sadushi-Kolici, Shahrokh Taghavi, Walter Klepetko, Hendrik Jan Ankersmit
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4154707?pdf=render
id doaj-811835498fb44929962af2928f749dbd
record_format Article
spelling doaj-811835498fb44929962af2928f749dbd2020-11-25T00:05:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10644010.1371/journal.pone.0106440Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.Bernhard MoserAnna MegerleChristine BekosStefan JanikTamás SzerafinPeter BirnerAna-Iris SchieferMichael MildnerIrene LangNika Skoro-SajerRoela Sadushi-KoliciShahrokh TaghaviWalter KlepetkoHendrik Jan AnkersmitOBJECTIVE:The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX). The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared sRAGE measurements to that of patients with aortic valve stenosis (AVS) - pressure overload of the left ventricle. METHODS:We enrolled patients with CTEPH(26), iPAH(15), AVS(15) and volunteers(33). Immunohistochemistry with antibodies to RAGE and HMGB1 was performed on PEA specimens and lung tissues. We employed enzyme-linked immunosorbent assays to determine the concentrations of sRAGE, esRAGE, HMGB1 and S100A9 in serum of volunteers and patients with CTEPH, iPAH, AVS before and after PEA, LuTX and aortic valve replacement (AVR). RESULTS:In endarterectomised tissues from patients with CTEPH RAGE and HMGB1 were identified in myofibroblasts (α-SMA+vimentin+CD34-), recanalizing vessel-like structures of distal myofibrotic tissues and endothelium of neointima. RAGE was differentially expressed in prototypical Heath Edwards lesions in iPAH. We found significantly increased serum concentrations of sRAGE, esRAGE and HMGB1 in CTEPH. In iPAH, sRAGE and esRAGE were significantly higher than in controls. Serum concentrations of sRAGE were significantly elevated in iPAH(p<0.001) and CTEPH(p = 0.001) compared to AVS. Serum sRAGE was significantly higher in iPAH compared to CTEPH(p = 0.042) and significantly reduced in AVS compared to controls(p = 0.001). There were no significant differences in sRAGE serum concentrations before and after surgical therapy for CTEPH, iPAH or AVS. CONCLUSIONS:Our data suggest a role for the RAGE pathway in the pathophysiology of CTEPH and iPAH. PEA improves the local control of disease but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE pathway.http://europepmc.org/articles/PMC4154707?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Bernhard Moser
Anna Megerle
Christine Bekos
Stefan Janik
Tamás Szerafin
Peter Birner
Ana-Iris Schiefer
Michael Mildner
Irene Lang
Nika Skoro-Sajer
Roela Sadushi-Kolici
Shahrokh Taghavi
Walter Klepetko
Hendrik Jan Ankersmit
spellingShingle Bernhard Moser
Anna Megerle
Christine Bekos
Stefan Janik
Tamás Szerafin
Peter Birner
Ana-Iris Schiefer
Michael Mildner
Irene Lang
Nika Skoro-Sajer
Roela Sadushi-Kolici
Shahrokh Taghavi
Walter Klepetko
Hendrik Jan Ankersmit
Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
PLoS ONE
author_facet Bernhard Moser
Anna Megerle
Christine Bekos
Stefan Janik
Tamás Szerafin
Peter Birner
Ana-Iris Schiefer
Michael Mildner
Irene Lang
Nika Skoro-Sajer
Roela Sadushi-Kolici
Shahrokh Taghavi
Walter Klepetko
Hendrik Jan Ankersmit
author_sort Bernhard Moser
title Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
title_short Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
title_full Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
title_fullStr Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
title_full_unstemmed Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
title_sort local and systemic rage axis changes in pulmonary hypertension: cteph and ipah.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description OBJECTIVE:The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX). The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared sRAGE measurements to that of patients with aortic valve stenosis (AVS) - pressure overload of the left ventricle. METHODS:We enrolled patients with CTEPH(26), iPAH(15), AVS(15) and volunteers(33). Immunohistochemistry with antibodies to RAGE and HMGB1 was performed on PEA specimens and lung tissues. We employed enzyme-linked immunosorbent assays to determine the concentrations of sRAGE, esRAGE, HMGB1 and S100A9 in serum of volunteers and patients with CTEPH, iPAH, AVS before and after PEA, LuTX and aortic valve replacement (AVR). RESULTS:In endarterectomised tissues from patients with CTEPH RAGE and HMGB1 were identified in myofibroblasts (α-SMA+vimentin+CD34-), recanalizing vessel-like structures of distal myofibrotic tissues and endothelium of neointima. RAGE was differentially expressed in prototypical Heath Edwards lesions in iPAH. We found significantly increased serum concentrations of sRAGE, esRAGE and HMGB1 in CTEPH. In iPAH, sRAGE and esRAGE were significantly higher than in controls. Serum concentrations of sRAGE were significantly elevated in iPAH(p<0.001) and CTEPH(p = 0.001) compared to AVS. Serum sRAGE was significantly higher in iPAH compared to CTEPH(p = 0.042) and significantly reduced in AVS compared to controls(p = 0.001). There were no significant differences in sRAGE serum concentrations before and after surgical therapy for CTEPH, iPAH or AVS. CONCLUSIONS:Our data suggest a role for the RAGE pathway in the pathophysiology of CTEPH and iPAH. PEA improves the local control of disease but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE pathway.
url http://europepmc.org/articles/PMC4154707?pdf=render
work_keys_str_mv AT bernhardmoser localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT annamegerle localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT christinebekos localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT stefanjanik localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT tamasszerafin localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT peterbirner localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT anairisschiefer localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT michaelmildner localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT irenelang localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT nikaskorosajer localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT roelasadushikolici localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT shahrokhtaghavi localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT walterklepetko localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT hendrikjanankersmit localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
_version_ 1725423488287637504